Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Santen Pharmaceutical Co ( (JP:4536) ).
Santen Pharmaceutical Co., Ltd. announced the status of its share buyback, repurchasing 3,046,100 common shares for a total of 5,055,157,200 yen between June 1 and June 30, 2025. This buyback is part of a larger plan approved by the Board of Directors to repurchase up to 19,800,000 shares, representing 5.8% of the total shares outstanding, with a maximum budget of 35 billion yen. This strategic move is likely to impact the company’s market positioning and shareholder value.
The most recent analyst rating on (JP:4536) stock is a Buy with a Yen1900.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company focused on eye health, providing products and services to patients, consumers, and medical professionals globally. With over 130 years of experience, Santen is involved in the research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries.
Average Trading Volume: 1,329,806
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen564.4B
For an in-depth examination of 4536 stock, go to TipRanks’ Overview page.